generic Advair trials, expected to last 6 weeks, will commence in the Summer. Candor has earmarked ADMP for a buyout upon the completion of APC-5000 trials.
beats on revenue, beats on eps. announces resumption of Azedra trials, initiation of clinical development of Mip 1095 and FDA indicated rescheduled ADCOM date VERY SOON.
bust thru 5 today
Lightbridge will hold a conference call and webcast on Friday, March 28, at 11 a.m. ET to discuss the Company's 2013 and fourth quarter results and provide an update on recent corporate developments.
11 am EST. no cooking questions allowed on the CC
yes there was limit on space!
THATS VERY POSITIVE NEWS
This is positive news
Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[124I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of 131I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of 131I-MIP-1095.
I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by 50 % in 60.7 % of the men treated
Based on the biodistribution and dose calculations of the PSMA-targeted small molecule 124I-MIP-1095 therapy with the authentic analog 131I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Involved lymph node and bone metastases were exposed to estimated absorbed doses upwards of 300 Gy.
and more about this MIP 1095 study released today.
gnx Mip-1095 Shows Clear Utility In Advanced mcrpc– Results Of A German Ist Buy Pt: $11.00 Investment Summary Recent clinical results with Progenics’ prostate cancer drug Mip-1095 demonstrated the drug’s ability to markedly reduce Psa levels in most of the heavily pretreated 25 evaluable of 28 patients treated. Mip-1095 is a small molecule anti-psma drug linked to radioactive iodine, that is both an imager (124i-mip-1095) and a therapeutic (131i-mip-1095). The report is from a German Ist that importantly demonstrates clinical utility even before an Ind is filed in the U.s. Progenics should file an Ind for Mip-1095 this year and initiate Phase 1 by Ye14, further broadening its prostate cancer imaging and treatment platform. Regarding efficacy, Psa values decreased by 50% in 61% of patients after one treatment cycle, including 25% of patients that had a 75% drop in Psa. Psa increased in 4 patients. Psa decreases were associated with a decrease in the number and/or intensity of the lesions visualized on posttherapeutic Pet/ct scans as seen by a dramatic reduction of tracer uptake in the tumor lesions. One patient had a durable Cr by serum Psa and radiographic imaging. For the 19 patients showing 25% decrease in Psa, median Ttp was 126 days (range 62 to 469 days). Regarding the bone pain that is so often associated with prostate cancer, 85% of 13 evaluated patients with bone pain showed complete or moderate pain reduction. More specifically, 23% (3/13) of patients experienced complete bone pain resolution and 62% (8/13) experienced a reduction in pain. 15% (2/13) of patients with bone pain had unknown outcomes.
Data was just released in Germany and confirmed by Brean Murray. BM Reiterating buy and $11 price target
Sentiment: Strong Buy
its nothing really. might give them more to time to decide to do a raise but that will b bought up very quickly IMO. i actually do see a positive in that PGNX announced its adcom date was being rescheduled from March 10 but up to now it hasn't announced the new date. ETRM announcing the new date, just 2 weeks after the original date, is not significant apart from the raise factor which will be a speed bump more than anything else
I know a lot of people love this MNKD cult but they are a dirty shady company with a wise CEO.
Deerfield is getting grid of the senior secured convertible notes, all 12 MILLION of them. what a mess
good summary, so much good news to come for this stock. the price in 5, 10 years time will be astronomic compared to where it is now